Analyst Jeffrey La Rosa of Leerink Partners maintained a Buy rating on Janux Therapeutics Inc, with a price target of $87.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jeffrey La Rosa’s rating is based on the promising clinical potential of Janux Therapeutics’ innovative tumor-conditional masking platform, which is expected to offer broader therapeutic windows for potent immuno-oncology treatments. The lead candidate, JANX007, a PSMA-targeted CD3 T-cell engager, shows potential for best-in-class efficacy, particularly in treating metastatic castration-resistant prostate cancer. The upcoming Phase 1 update in the second half of 2025 presents an attractive risk-reward scenario, with expectations of improved safety and efficacy through dose and schedule optimization.
Moreover, Janux’s second program, JANX008, targeting EGFR-expressing solid tumors, is also progressing towards a Phase 1 update. While expectations for this program are modest, there is potential for positive surprises in certain settings. Additionally, Janux’s collaboration with Merck and the advancement of their early-stage programs further bolster confidence in the company’s strategic direction. These factors collectively contribute to the Buy rating for Janux Therapeutics’ stock.
In another report released on August 13, Bank of America Securities also maintained a Buy rating on the stock with a $59.00 price target.
JANX’s price has also changed moderately for the past six months – from $36.110 to $22.670, which is a -37.22% drop .